Pfizer Bids Farewell To Blue Pill With New Double Helix Logo
'Reveals DNA At Heart' Of Science-Focused Firm
CEO Albert Bourla says the rebranding "marks the advent of the new Pfizer – the culmination of a bold, decade-long transformation from a scientific fast follower to a first-in-class scientific powerhouse."
You may also be interested in...
Join us for an audio catch-up on the latest major developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.
Great progress has been made in the treatment of RA with biologics and JAK inhibitors but there is a space for effective small-molecule therapies and Aclaris hopes to fill it with ATI-450.